Chemotherapy has been used in clinical practice for approximately twenty years and the subject has now come of age. While it is still true that the majority of common malignancies are not amenable to treatment with cytotoxic drugs, there are a few human tumours, notably chorioepithelioma, Burkitt's lymphoma and lymphoblastic leukemia, which are curable by drugs alone. In other tumours the cure rate is increasing with the combined use of radiotherapy and chemotherapy and there is reason to believe that Hodgkin's disease is in this category. Because of this possibility it is important that the right drugs be applied at the right time and in the right way.
Localized Hodgkin's disease should be treated by radiotherapy, but before deciding that it is the treatment of choice a very detailed investigation of the patient must be made to delineate the true extent of the disease. This investigation must include X-rays of the chest, lymphangiography and intravenous pyelography, as well as liver function tests, ESR and blood count. Liver and spleen scanning may be helpful but laparotomy with splenectomy is being advocated now as a means of increasing the accuracy of staging.
If the disease is widespread, chemotherapy is the treatment of choice, especially if the patient has fever, sweats or weight loss.
Many drugs have been found useful in the treatment of Hodgkin's disease, including vinblastine and cyclophosphamide, but with single agents, given continuously in relatively low doses, complete remission has rarely occurred in more than 25 % of cases. More recently combinations of cytotoxic drugs have been given with a view to increasing their anti-tumour effect while not increasing their toxicity. The best regime so far devised consists of vincristine 1.5-2.0 mg given intravenously on Days 1 and 8 and mustine hydrochloride 6-10 mg intravenously on Days 1 and 8, together with procarbazine 50-150 mg and prednisone 40 mg orally, daily from Days 1 to 8 inclusive. This regime is usually referred to as MOPP.
When given to patients with recurrent Hodgkin's disease, remission is achieved in most patients and is complete in 50-60%. In our own series at the Royal Marsden Hospital the median length of complete remissions was 23 months. Complete remissions are achieved in 75 % of cases if MOPP is given as a first treatment and the median length of remission in one large prospective study was 96 weeks, compared with 55 weeks using vinblastine and cyclophosphamide singly.
The MOPP regime is given at least six times over approximately six months and studies are under way to see whether some kind of maintenance therapy after six months of MOPP can increase the length of remissions still further. The treatment is inconvenient for a patient who is feeling well and is at work, but is not dangerous if given properly. Treatment of the poorly differentiated lymphoma, that is lymphosarcoma and reticulum cell sarcoma, has been following similar lines to those just described. Unfortunately the results of treatment even for local disease have not been as good as in Hodgkin's disease. This may be due to earlier dissemination which is not treated by local radiotherapy, and chemotherapy is now being given to patients earlier in the hope of improving results. When the disease is widespread, complete remissions can be achieved in approximately 80% of cases but the median length of remissions is disappointingly short, approximately 35 weeks. Again, combination chemotherapy is better than single agents, but in this case a combination of cyclophosphamide, prednisone and vincristine has proved most effective.
The results, then, in poorly differentiated non-Hodgkin's lymphoma, are disappointing. However, since it is known that in animal tumours the correct choice of drugs, dose schedules and timing of therapy may be all-important in producing a good cure rate, we may be optimistic that more effective regimes will be available in the near future.
